Advances in BABE

 In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

 

  • Application of Nano technology to improve bioavailabilty
  • Innovative strategies
  • Isotope drug studies in man
  • Bioequivalence Criteria
  • Risks in bioequivalence assessment
  • Requirement to determine the active principle
  • Relevance of bioequivalence in approving generic copies of drug products
  • Electronic regulatory submission and review
  • Electronic regulatory submission and review
  • Drug application regulatory compliance
  • New drug quality assessment
  • Highly variable and low permeable drugs
  • Complex generics

Related Conference of Advances in BABE

December 14-14, 2020

2nd Pathology and Infectious Disease Conference

Dubai, UAE
March 28-29, 2021

11th Glycobiology World Congress

Vienna, Austria
April 24-24, 2021

2nd International Conference on Nucleic Acids

London, UK
June 11-12, 2021

25th Global Congress on Biotechnology

Berlin, Germany
September 13-14, 2021

17th World Congress on Structural Biology

Prague, Czech Republic
September 27-28, 2021

25th European Biotechnology Congress

Dublin, Ireland

Advances in BABE Conference Speakers

Recommended Sessions

Related Journals

Are you interested in